Change in mean hemoglobin level, percentage of patients transfused during the study, and mean number of units of blood transfused during months 2 and 3 of the study
| Treatment . | Baseline Endogenous EPO (mU/mL) . | N . | Mean Baseline Hb (g/dL) . | Mean Final Hb (g/dL) . | Mean Hb Change (g/dL)3-150 . | Number (%) Hb Responders . | % Patients Transfused with RBCs . | Mean Units of RBC Transfused During Months 2 & 3 . |
|---|---|---|---|---|---|---|---|---|
| GM-CSF + epoetin alfa | ≤500 | 25 | 9.34 | 9.40 | +0.04 | 4 (16) | 603-152,3-153 | 5.93-155 |
| GM-CSF + placebo | ≤500 | 12 | 9.38 | 8.45 | −0.92 | 1 (8) | 92 | 9.5 |
| GM-CSF + epoetin alfa | >500 | 20 | 8.49 | 8.60 | +0.073-151 | 0 | 95 | 9.73-154 |
| GM-CSF + placebo | >500 | 9 | 8.67 | 7.62 | −0.96 | 0 | 89 | 8.6 |
| All epoetin alfa patients | — | 45 | 8.96 | 9.04 | +0.06 | 4 (9) | 76 | 7.6 |
| All placebo patients | — | 21 | 9.08 | 8.09 | −0.95 | 1 (5) | 90 | 9.1 |
| Treatment . | Baseline Endogenous EPO (mU/mL) . | N . | Mean Baseline Hb (g/dL) . | Mean Final Hb (g/dL) . | Mean Hb Change (g/dL)3-150 . | Number (%) Hb Responders . | % Patients Transfused with RBCs . | Mean Units of RBC Transfused During Months 2 & 3 . |
|---|---|---|---|---|---|---|---|---|
| GM-CSF + epoetin alfa | ≤500 | 25 | 9.34 | 9.40 | +0.04 | 4 (16) | 603-152,3-153 | 5.93-155 |
| GM-CSF + placebo | ≤500 | 12 | 9.38 | 8.45 | −0.92 | 1 (8) | 92 | 9.5 |
| GM-CSF + epoetin alfa | >500 | 20 | 8.49 | 8.60 | +0.073-151 | 0 | 95 | 9.73-154 |
| GM-CSF + placebo | >500 | 9 | 8.67 | 7.62 | −0.96 | 0 | 89 | 8.6 |
| All epoetin alfa patients | — | 45 | 8.96 | 9.04 | +0.06 | 4 (9) | 76 | 7.6 |
| All placebo patients | — | 21 | 9.08 | 8.09 | −0.95 | 1 (5) | 90 | 9.1 |
Adjusted according to linear model analysis (least-squares mean).
Significantly different from >500 mU/mL endogenous erythropoietin/placebo group, P = .048.
Marginally lower than in 500 mU/mL endogenous erythropoietin + placebo group, P = .0510.
Statistically significantly lower than in >500 mU/mL endogenous erythropoietin + epoetin alfa group, P = .0069.
P = .09; epoetin vs. placebo for endogenous erythropoietin 500.
P = .62; epoetin vs. placebo for endogenous erythropoietin >500.